Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
In the post-pandemic COVID-19 period, human activities have returned to normal and
COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an …
COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an …
Real-world clinical outcomes of molnupiravir for the treatment of mild to moderate COVID-19 in adult patients during the dominance of the Omicron variant: a meta …
C Huang, TL Lu, L Lin - Antibiotics, 2023 - mdpi.com
Introduction: The therapeutic impact of molnupiravir in the Omicron variant phase is
unknown. The goal of the current meta-analysis was to compare the real-world clinical …
unknown. The goal of the current meta-analysis was to compare the real-world clinical …
Factors associated with pneumonia in patients hospitalized with COVID-19 and the role of vaccination
Patients with COVID-19 can develop different forms of the illness with more or less severe
symptoms. A 2-year retrospective cohort study was conducted to evaluate the factors …
symptoms. A 2-year retrospective cohort study was conducted to evaluate the factors …
Assessing antiviral treatment efficacy and risk factors for severe COVID-19 in kidney transplant recipients during the Omicron subvariant-dominant period: a …
T Sakaguchi, A Mitsuke, Y Osako, Y Yamada… - BMC nephrology, 2024 - Springer
Abstract Background Kidney transplant recipients (KTRs) are at risk of severe coronavirus
disease 2019 (COVID-19), and even now that Omicron subvariants have become dominant …
disease 2019 (COVID-19), and even now that Omicron subvariants have become dominant …
Evaluation of the efficacy and safety of nirmatrelvir/ritonavir co-administration inpatients with rheumatic disease infected with SARS-CoV-2: a real-world study
X Zhong, C Wang, L Huang, Y Zhao, T Li… - Frontiers in …, 2023 - frontiersin.org
Background: The breakthrough development of novel severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) vaccines and oral antivirals have played a critical role in …
coronavirus-2 (SARS-CoV-2) vaccines and oral antivirals have played a critical role in …
Estimation of intangible costs for factors associated with oral antiviral drugs for COVID-19 Treatment: A conjoint analysis in Japan
N Hosogaya, T Takazono, K Kurazono, S Hiroi… - Advances in …, 2023 - Springer
Introduction During the recent coronavirus disease 2019 (COVID-19) pandemic, preferences
for factors associated with vaccines have been evaluated. Three oral antiviral drugs have …
for factors associated with vaccines have been evaluated. Three oral antiviral drugs have …
Real-World Utilization of Molnupiravir during the COVID-19 Omicron Surge in Israel
C Weil, T Bergroth, A Eisenberg, YO Whiteside… - Epidemiologia, 2023 - mdpi.com
Molnupiravir (MOV) was introduced in Israel in January 2022 during the SARS-CoV-2
Omicron surge for high-risk patients contraindicated for nirmatrelvir/ritonavir. This …
Omicron surge for high-risk patients contraindicated for nirmatrelvir/ritonavir. This …
[HTML][HTML] Safety of RNA-Dependent RNA Polymerase Inhibitors, Molnupiravir and VV116, for Oral Treatment of COVID-19: A Meta-Analysis
Z Zheng, J Zhou, Y Song - Iranian Journal of Medical Sciences, 2024 - ncbi.nlm.nih.gov
Background: The RNA-dependent RNA polymerase (RdRp) inhibitors, molnupiravir and
VV116, have the potential to maximize clinical benefits in the oral treatment of COVID-19 …
VV116, have the potential to maximize clinical benefits in the oral treatment of COVID-19 …
Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the …
Background Comparative data on mortality in COVID-19 patients treated with molnupiravir
or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause …
or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause …
OPEN ACCESS EDITED BY
A Saffaei, I Education, H Yousefian… - The Evolution in …, 2024 - books.google.com
Tylosin belongs to the macrolide family of antibiotics, which share a macrocyclic lactone ring
structure critical for their antibacterial activity (Arsic et al., 2018). Variations in this ring …
structure critical for their antibacterial activity (Arsic et al., 2018). Variations in this ring …